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ABSTRACT: Experimental studies suggest that the b-blocker propranolol stimulates bone formation but little work has investigated its
effect on fracture healing. In this study, we examined if a low dose of propranolol, previously shown to be preventive against bone loss
in rats, improves bone repair. Female Wistar rats were injected with saline or propranolol (0.1mg/kg/day) (n¼20/group), 5 days a week
for 8 weeks. Three weeks after the beginning of treatment, all rats underwent a mid-diaphyseal transverse osteotomy in the left femur.
Radiographic analysis of ostetomy healing was performed 2 and 5 weeks after osteotomy. Rats were sacrificed at 5 weeks and femora
collected for measurements of fracture strength by torsional testing, callus volume, and mineral content by micro-CT analysis and
histology of fracture callus. Eighty nine percent of osteotomies achieved apparent radiological union by 5 weeks in both groups.
Propranolol treatment did not significantly alter the torsional strength of the fractured femur compared with controls. The volume and
mineralization of fracture callus at 5 weeks were not significantly different in both groups. Histology showed that endochondral
ossification was not affected by propranolol. Altogether, our results demonstrate that propranolol using the regimen described does not
significantly improve or inhibit rat osteotomy healing and mechanical strength.  2014 The Authors. Journal of Orthopaedic Research
Published by Wiley Periodicals, Inc. J Orthop Res 32:887–893, 2014.
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Bone and periosteum are richly innervated by sympa-
thetic and sensory nerves processes running in the
vicinity to bone marrow and bone cells1–4 and neural
regulation of bone metabolism has been extensively
demonstrated in vitro and in vivo involving these
different components of the nervous system.5–9 More
interest was recently generated regarding the role of
the sympathetic nervous system (SNS) in bone, due
to the major discovery of a leptin-dependent central
control pathway of bone remodeling involving the
SNS.10 Bone cells have indeed functional receptors for
several neuromediators, including noradrenergic
receptors (AR).11–13 Osteoblasts and osteoclasts consti-
tutively express the beta-2 adrenergic receptor (b2AR),
which appears to be the main adrenergic receptor in
bone cells, although b1, a1B, and a2BAR could also
play a role in bone cell function.8,14,15 Multiple in vitro
and in vivo studies have shown that b2AR activation
inhibits bone formation while osteoclastogenesis and
bone resorption are increased.8,14,16 In accordance,
bAR antagonists (b-blockers) increase bone formation
rate and can significantly rescue the bone loss induced
by ovariectomy (OVX).10,13,17–19 Their effects on bone
metabolism seem however dose-dependent, low doses
being more protective against bone loss.17,18
The demonstration that b-blockers can increase
bone mass in rodent experiments has led to the
assumption that these drugs may play an important
role in preventing bone loss and improving fracture
healing in humans, in addition to treat cardiovascular
disease. Several clinical retrospective studies have
examined the use of b-blockers as potential therapeu-
tic options for the bone loss observed in osteoporosis
and associated fragility fractures but their results
were conflicting, indicating the need for more random-
ized controlled trials to confirm the beneficial effect of
b-blockers on bone mass and fracture risk.19–21 While
animal studies have shown that complete peripheral
nerve transection impairs fracture healing22,23 and
that sensory innervation contributes to fracture heal-
ing,5,24 the role of the SNS and b-blockers on normal
and fragility fracture healing has been poorly studied.
Vascularization is essential for fracture healing and
the SNS could be involved in bone formation during
fracture repair, either directly through b2AR
expressed on bone cells or indirectly through modula-
tion of bone blood flow.25 The increase in autonomic
innervation after fracture suggests indeed that this
component of the nervous system plays a role in
fracture repair.26 The only study performed in rats
showed a positive effect of 19 days propranolol treat-
ment on the union of 5mm bone defects packed with
demineralized bone matrix powder, suggesting that
b-blockers could be beneficial to fracture healing.27
The aim of this study was to explore the hypothesis
than 8 weeks injections of propranolol at a low dose of
0.1mg/kg/day would induce beneficial changes in cal-
lus formation and strength during fracture healing in
a 0.5mm mid-diaphyseal transverse osteotomy model
in the rat femur.
MATERIAL AND METHODS
Study Design
To examine the effect of propranolol on osteotomy healing,
two different experiments were performed with the same
protocol, one to enable destructive mechanical testing of
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fracture callus and the other one to measure callus volume
and mineralization and perform morphological examinations.
In both experiments, 20 female Wistar rats of approximately
250–300 g were divided randomly into two groups, one
(n¼ 10) was injected with saline while the other (n¼ 10) was
injected intraperitoneally with propranolol (0.1mg/kg/day), 5
days a week for 8 weeks. Sample size was based on our
previous experience and calculated so that 10 rats per group
for each comparison are sufficient to establish significant
differences between groups. Drinking water, along with food,
was available ad libitum. Three weeks after the beginning of
propranolol treatment all rats (n¼ 20) underwent a mid-
diaphyseal transverse osteotomy (with a gap of 0.5mm) in
the left femur stabilized with an external fixator, as
described previously.28,29 These procedures were performed
under general anaesthesia with appropriate post-operative
analgesia. Rats were kept 5 weeks after surgery and then
euthanized under anaesthesia. Right and left femora were
excised immediately after death at 5 weeks for mechanical
testing in the first experiment and micro-CT analysis of
fracture callus and histology in the second one. All animal
experimentation procedures were in compliance with local
ethical committee and Home Office approval and were
performed under license in accordance with UK Animals
(Scientific Procedures) Act 1986.
Radiographic Analysis
Both dorsal and ventral radiographs were taken at 2 weeks
and 5 weeks under anaesthesia to assess the extent of in situ
healing in terms of bridging of cortices across the osteotomy
gap. The degree of union was scored on X-rays using a five
point system, as previously described30; 0—no callus, 1—
little to moderate callus, 2—profuse callus, 3—bridging
callus, 4—mature callus with intrafragmentary bridging, 5—
callus resorption after solid union.
Biomechanical Analysis
Femora were excised immediately after sacrifice at 5 weeks,
individually stored in saline soaked gauze and frozen at 20˚
C. Immediately before testing, they were thawed and im-
mersed in saline solution during the whole analysis. The
torsional properties of osteotomized femora relative to those
of intact contralateral ones were measured using the tech-
nique of Stro¨mberg and Dale´n31 using a Zwick/Roell (Slin-
fold, UK) testing machine DO-FB005 TN (Maximum test
load 5000N). Torque was applied with a consistent angular
velocity of 6˚ per second, with consistent direction, until
failure. The torque and deflection angle were recorded using
customized computer software. Graphical representation of
torque versus angle permitted quantification of the maxi-
mum torque at failure (ultimate torsional strength, Nm) and
the torsional stiffness (slope of the linear region of the torque
versus angular displacement curve (Nm/deg)).
Micro-CT Analysis of Fracture Callus
Left femora (fractured side) were scanned at 14mm resolu-
tion using micro-computed tomography (micro-CT, Skyscan
1172, Kontich, Belgium). A length of approximately 15mm
of the callus with the osteotomy in the centre was scanned
and histomorphometric analysis in 2- and 3- dimensions
(2D, 3D) performed by Skyscan software (v. 1.11.8.0), as
described.29 Binarization of the reconstructed datasets in-
volved two thresholds, one to delineate the low mineralized
callus and the other one to define mineralized callus and
cortical bone.
Figure 1. Expression of beta-2 adrenergic receptor in the osteotomy gap. (A) Representative image of Alcian blue-stained section of
control fracture callus 5 weeks after fracture. The osteotomy gap (o), cortical bone (c) and bone marrow (bm) are indicated. (B) Higher
magnification of the region shown in the box in section A and stained with H&E. Hypertophic chondrocytes (HC) and osteoblasts or
osteoblast progenitors (Ob) are indicated by an arrow. (C) Image of osteotomy gap showing the presence of b2AR indicated by green
fluorescence. (D) Same image of osteotomy gap showing the nuclei of cells. (E) Merge of CþD (Scale bars¼50mm). (F) Negative control
(no primary antibody).
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Histology
After micro-CT analysis, fracture calluses were decalcified
and embedded in paraffin as described previously.29 Sagittal
sections (5mM) were cut in standardized plane using a
microtome (HM360, Fisher Scientific Ltd, Loughborough,
UK) and stained with Hematoxylin and Eosin (H&E) for
basic morphology or Alcian blue and nuclear fast red for
analysis of cartilage and bone.
Immunofluorescence
Sections of the osteotomy region were dewaxed, dehydrated,
and incubated for 45min at 37˚C in pepsin (3mg/ml in
0.02M HCl) for antigen retrieval, then foetal calf serum
(FCS) for 30min to block non-specific binding. They were
incubated with a primary rabbit antibody to b2AR (Thermo
Scientific Pierce, Rockford, IL) at 1:1,000 in 20% FCS at 4˚C
overnight, washed and incubated with an anti-rabbit sec-
ondary antibody labelled with biotin (Dako, Carpinteria,
CA) for 1 h at room temperature. Sections were washed,
incubated with streptavidin-488 for 15min, rinsed and
mounted with a medium containing 40,6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI) for visualization of
nucleic acids.
Statistical Analysis
The results are presented as mean valuesSD. Statistical
analysis was performed using a two-tailed Mann Whitney
U test with GraphPad Prism software.
RESULTS
Beta-2 Adrenergic Receptor Was Highly Expressed in
Fracture Callus
Detection of b2AR was carried out by immunocyto-
chemistry on sections of the osteotomy region in the
non-treated group (Fig. 1A). Figure 1B illustrates the
area of section examined. Immunofluorescence for
b2AR (Fig. 1C) is highly detected in the osteotomy gap
and dissipated when moving further away from the
osteotomy site. Increased magnification fluorescence
images taken of the osteotomy site clearly showed that
the fluorescence was more abundant in bone-forming
osteoblasts rather than in hypertrophic chondrocytes.
Our staining suggested that b2AR expression was
mainly cytoplasmic.
Propranolol Had No Significant Effect on Body Weight and
Radiographic Healing
Eight weeks propranolol treatment had no effect on
body weight in both experiments (Fig. 2A). At 2 weeks,
only 10% of osteotomies showed radiographic healing
in one of the cortices. At 5 weeks, 89% of osteotomies
achieved apparent radiological union in both groups
(Fig. 2B).
Propranolol Treatment Did Not Significantly Improve the
Mechanical Strength of the Fractured Femur
Torque-to-failure testing was performed 5 weeks after
osteotomy, a time that gave sufficient healing to
undergo testing. Propranolol treatment had no signifi-
cant effect on the strength (Fig. 3A) and stiffness
(Fig. 3C) of the fractured femur compared with
controls. There was however a trend for increases in
both strength and stiffness in the propranolol-treated
group, close to significance in case of strength (Fig. 3A,
20%, P¼ 0.06). While intrinsic material properties of
the intact femur were similarly not significantly modi-
fied by propranolol (Fig. 3B,D), the strength of the
operated femur was 27% and 46% of the contralateral
intact femur in saline- and propranolol-treated groups,
respectively.
Propranolol Treatment Did Not Affect Fracture
Callus Size or Mineralization
In both control and propranolol-treated groups, a large
callus was still visible at the osteotomy site (Fig. 4A).
Two binarization thresholds were applied to the micro-
CT images of fracture calluses, one which took into
account the low mineralized callus solely (Fig. 4Bi),
the other one only taking into account cortical bone
and highly mineralized callus (Fig. 4Bii). Propranolol
treatment did not significantly affect either the vol-
umes of low mineralized callus or that of highly
mineralized callus and cortical bone (Fig. 4B).
Figure 2. Effect of propranolol treatment on rat body weight
and bone radiographic healing. (A) Body weight at start and end
of propranolol treatment period in saline and propranolol-treated
rats. (B) X-ray scoring results for fractured femora in saline and
propranolol-treated rats 5 weeks after fracture. Bars represent
meanSD of n¼ 8/9 rats/group.
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Propranolol Treatment Had No Effect On Endochondral
Ossification
Figure 5Ai and Bi shows representative images of
H&E- stained fracture calluses at 5 weeks in saline
(A) and propranolol (B)-treated groups. In both groups,
the periosteal callus still contained cartilage as well as
small regions of primary trabecular-like bone. Higher
magnifications of cartilage in the callus demonstrate
hypertrophic chondrocytes in both propranolol-treated
(Bii) and control group (Aii), suggesting that proprano-
lol does not induce substantial advanced osteotomy
healing.
DISCUSSION
While many studies have investigated the role of
propranolol on fracture risk, its crucial role in bone
repair has not been extensively examined. In this
study, we demonstrate that osteotomy healing and
callus strength were not significantly improved by
propranolol treatment at the dose used.
To examine the effect of propranolol on bone repair,
we used a model of mid-diaphyseal transverse osteot-
omy in rats, routinely employed in our lab.28,29 The
osteotomy was stabilized by external fixation, which
provided greater control of the mechanical environ-
ment and thus a better assessment of the effect of
propranolol treatment alone. Rats were injected with a
low dose of propranolol, previously used to prevent
bone loss in OVX rats.17 Propranolol effects on the
skeleton were dose-dependent in rodent models, low
doses of 0.1 and 1mg/kg being beneficial for preserving
bone mass in OVX rats while higher doses having
mainly no effect on bone architecture,17,32–34 although
propranolol treatment at 20mg/kg was shown to
reduce the unloading-induced bone loss in mice.35
Different delivery modes of propranolol were also
used,10,28,32,33,35 and most studies agree that doses of
propranolol ranging from 0.1 to 5mg/kg (intraperitone-
al injections) are efficient to prevent cancellous bone
loss after estrogen deficiency and disuse. However, the
mechanisms of action are not always concordant as
some studies suggest predominant effects on bone
resorption while others show that propranolol
increases osteoblast number and bone formation
rate.20 Most studies have examined the skeletal effect
of propranolol in models of bone loss. In our study,
Figure 3. Effect of propranolol treatment on fracture callus mechanical properties. (A,B) Mean peak torque (Nm) in fractured (A) and
intact (B) femur after 5 weeks of healing in saline and propranolol-treated groups. (C,D) Stiffness (Nm/deg) in fractured (C) and intact
(D) femur after 5 weeks of healing in saline and propranolol-treated groups. Bars represent meanSD of n¼ 8/9 tested rats/group.
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rats were not OVX or immobilized. The low proprano-
lol dose that we used did not affect body weight, in
accordance with previous studies in rodents.32,33,35
Both intramembranous and endochondral ossifica-
tion are taking place during bone regeneration.36 We
evaluated the effect of propranolol 5 weeks after
fracture, a time at which complete periosteal bridging
had occurred in the model used but where cartilage
persisted in the fracture callus, suggesting that endo-
chondral ossification was still taking place. Our pres-
ent histology data corroborate this and do not indicate
that the rate of chondrocyte maturation in the perios-
teal fracture callus was different in the propranolol-
treated group compared to controls. We also showed
no effect of propranolol on callus size and density of
mineral, although there was a trend for a decrease in
low mineralized callus in the propranolol group,
suggesting that mineralization and therefore speed of
healing could be slightly more rapid in this group.
While our power calculation has shown that 10 rats/
group was sufficient to show significant effects in this
osteotomy model, we cannot exclude that propranolol
may have a significant positive effect on mineraliza-
tion with the use of larger groups. However, a more
rapid mineralization of the cartilaginous callus in the
propranolol-treated group would indicate that pro-
pranolol affects mechanical qualities of the fracture
callus and our present data show no significant effects.
Mechanical integrity was evaluated by torsional test-
ing, a widely used method since it most closely mimics
physiologic loading in vivo and accommodates the
callus asymmetry.37 Callus torsional strength was not
significantly enhanced by propranolol after 5 weeks
treatment, despite small increases in callus stiffness
and strength in the propranolol-treated group which
could correlate with the little increase in mineral
content within the external callus. Correlations be-
tween fractured and intact femurs show that, 5 weeks
after osteotomy, propranolol- treated group had
reached 46% of the strength of the contralateral intact
femur against 27% for the saline group, confirming the
tendency for enhanced strength of the fractured bones
in the propranolol group, although this result was not
statistically significant.
One single publication reported the effect of pro-
pranolol on bone repair in a rat femoral defect model
of 5mm packed with demineralized bone matrix.
Propranolol treatment for 19 consecutive days, at
Figure 4. Effect of propranolol treatment on fracture callus size and mineralization. (A) Representative micro-CT images of control (i)
and propranolol-treated (ii) fractured femora. (B) The volumes of low mineralized callus (i) and highly mineralized callus and bone (ii)
are not significantly different in control and propranolol-treated groups. Bars represent meanSD of n¼8/9 rats/group. Examples of
visual representations of the proportion of low mineralized callus highlighted in pink and high-mineralized callus and bone highlighted
in yellow are shown below the graphs.
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similar range of doses to our study, significantly
increased callus formation by 33% as well as mineral
apposition rate measured after 12 weeks by densitom-
etry and histology, respectively.27 In contrast, prelimi-
nary work by Aspenberg’s group38 and Bostrom et al.39
indicated no effect of propranolol on bone healing of
osteotomized mice. In this latest report, propranolol
was added in the drinking water at low (4mg/kg) and
high (20mg/kg) doses for 3 weeks and no significant
difference between treatments was demonstrated.
While propranolol was started at time of osteotomy in
previous studies, we administered propranolol 3 weeks
before osteotomy to mimic fractures in patients on pre-
existing propranolol. We cannot exclude that greater
effects could be present by delaying the administration
of propranolol until the bone anabolic response after
osteotomy or by performing the analysis at later time
points. The weakness of all these studies, ours includ-
ed, is also that the efficacy of propranolol treatment
was not evaluated in terms of expected pharmacologi-
cal action, as the effect of propranolol was not assessed
on blood flow parameters. Fracture healing like any
wound healing is a well-coordinated process that
requires cell migration and proliferation at the wound.
Interestingly, b2AR activation decreased cell migra-
tion and proliferation, delaying wound healing, while
in contrast blockade of b2AR by antagonists promoted
wound repair, partly by increasing angiogenesis.40
Fracture healing requires revascularization and
nerves, which are frequently associated with blood
vessels and may also affect fracture healing indirectly
via their effects on angiogenesis and blood flow.
Propranolol is an unspecific b-blocker but most effects
on bone of bAR signalling seem to be mediated by
b2AR expressed by bone cells,18,19 although other bAR
subtypes may contribute to the regulation of bone
mass by having different or even opposite effects on
bone.14,15 We found high expression of b2AR in the
fracture callus, supporting a role for adrenergic nerves
in the process of bone healing. The SNS plays a very
important role in osteoporosis and other osteoporotic
conditions such as spinal cord injury and reflex
sympathetic dystrophy syndrome,21 which are impor-
tant clinical issues contributing to a high number of
fractures each year in the UK. The possible role of
beta-blockers in the maintenance of bone mass and
improvement of fracture healing in those patients may
therefore depend on the development and use of highly
selective beta-blockers.
In conclusion, our data indicate that low dose of
propranolol had no significant positive or negative
effect on bone healing and callus strength in a rodent
model of osteotomy. Although this dose has been
previously proven to be effective on bone mass, our
study is limited by the use of this single dose of
propranolol without any measurement of its efficacy
on bone flow parameters in our model. A single agent
such as propranolol that could have beneficial effects
on both the heart and bone could have huge signifi-
cance in terms of public health. However, our study
indicates that the commonest clinical setting would be
simple fractures in patients on pre-existing proprano-
lol for its cardiac benefit.
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